Ironwood Pharmaceuticals, Inc. (IRWD)
US — Healthcare Sector
Automate Your Wheel Strategy on IRWD
With Tiblio's Option Bot, you can configure your own wheel strategy including IRWD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
IRWD's Q4 Earnings and Revenues Fall Shy of Estimates, Stock Down
IRWD
Published: February 28, 2025 by: Zacks Investment Research
Sentiment: Negative
Published: February 28, 2025 by: Zacks Investment Research
Sentiment: Negative
Ironwood reports weaker-than-expected results for the fourth quarter of 2024. The company maintains total revenue guidance for 2025.
Read More
About Ironwood Pharmaceuticals, Inc. (IRWD)
- IPO Date 2010-02-03
- Website https://www.ironwoodpharma.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Thomas A. McCourt
- Employees 253
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.